{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:00:47Z","timestamp":1792868447893,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed\/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) \u201cAdditional Concerns\u201d neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)\/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Of 929 randomized patients, 911 with \u22651 post-baseline assessment were included. Kd56 was associated with statistically significant improvements in GHS\/QoL, fatigue, pain, side effects, and FACT\/GOG-Ntx scores versus Vd, although mean differences did not meet thresholds for clinical significance. The Kd56 group had longer time to deterioration (TTD) in GHS\/QoL (median 3.7 versus 2.8 months,<jats:italic>p<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u20090.0046), physical function (5.6 versus 3.7 months,<jats:italic>p<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u20090.0390), nausea\/vomiting (17.6 versus 8.2 months,<jats:italic>p<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u20090.0358), side effects (6.4 versus 3.7 months<jats:italic>p<\/jats:italic>\u2009<jats:italic>&lt;<\/jats:italic>\u20090.0001), and FACT\/GOG-Ntx (11.1 versus 5.5 months<jats:italic>, p<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u20090.0004). Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS\/QoL scores versus Vd. Treatment with Kd56 versus Vd also significantly prolonged TTD in GHS\/QoL, physical function, nausea\/vomiting, side effects, and FACT\/GOG-Ntx.<\/jats:p>","DOI":"10.1038\/s41408-019-0181-0","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T16:04:10Z","timestamp":1550851450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"9","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"181_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"181_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld, P. et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 27, 1959\u20131969 (2013).","journal-title":"Leukemia"},{"key":"181_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","volume":"72","author":"N Gulbrandsen","year":"2004","unstructured":"Gulbrandsen, N. et al. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur. J. Haematol. 72, 172\u2013180 (2004).","journal-title":"Eur. J. Haematol."},{"key":"181_CR4","doi-asserted-by":"crossref","unstructured":"Kvam, A. K. & Waage, A. Health-related quality of life in patients with multiple myeloma\u2013does it matter? Haematologica 100, 704\u2013705 (2015).","DOI":"10.3324\/haematol.2015.127860"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 18, 1327\u20131337 (2017).","journal-title":"Lancet Oncol."},{"key":"181_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","volume":"36","author":"K Bjordal","year":"2000","unstructured":"Bjordal, K. et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur. J. Cancer 36, 1796\u20131807 (2000).","journal-title":"Eur. J. Cancer"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","volume":"104","author":"ML Stead","year":"1999","unstructured":"Stead, M. L. et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br. J. Haematol. 104, 605\u2013611 (1999).","journal-title":"Br. J. Haematol."},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun, E. A. et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int. J. Gynecol. Cancer 13, 741\u2013748 (2003).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks, K. et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer 43, 1670\u20131678 (2007).","journal-title":"Eur. J. Cancer"},{"key":"181_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-8-79","volume":"8","author":"AK Kvam","year":"2010","unstructured":"Kvam, A. K., Wisloff, F. & Fayers, P. M. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual. Life Outcomes 8, 79 (2010).","journal-title":"Health Qual. Life Outcomes"},{"key":"181_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","volume":"92","author":"F Wisloff","year":"1996","unstructured":"Wisloff, F. et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br. J. Haematol. 92, 604\u2013613 (1996).","journal-title":"Br. J. Haematol."},{"key":"181_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","volume":"143","author":"SJ Lee","year":"2008","unstructured":"Lee, S. J. et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br. J. Haematol. 143, 511\u2013519 (2008).","journal-title":"Br. J. Haematol."},{"key":"181_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois, D. et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J. Clin. Oncol. 24, 976\u2013982 (2006).","journal-title":"J. Clin. Oncol."},{"key":"181_CR15","first-page":"574","volume":"100","author":"DS Siegel","year":"2015","unstructured":"Siegel, D. S. et al. Impact of carfilzomib on health-related quality of life: results from a phase 2 post-hoc analysis of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Haematologica 100, 574 (2015).","journal-title":"Haematologica"},{"key":"181_CR16","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.3639","volume":"28","author":"GF Liu","year":"2009","unstructured":"Liu, G. F., Lu, K., Mogg, R., Mallick, M. & Mehrotra, D. V. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat. Med. 28, 2509\u20132530 (2009).","journal-title":"Stat. Med."},{"key":"181_CR17","doi-asserted-by":"crossref","unstructured":"Mallinckrodt C., Lipkovich I. Analyzing Longitudinal Clinical Trial Data: A Practical Guide (CRC Press, Taylor & Francis Group, Danvers, MA, 2016).","DOI":"10.1201\/9781315186634"},{"key":"181_CR18","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","volume":"10","author":"DL Patrick","year":"2007","unstructured":"Patrick, D. L. et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10, S125\u2013S137 (2007).","journal-title":"Value Health"},{"key":"181_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks, K. et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J. Clin. Oncol. 29, 89\u201396 (2011).","journal-title":"J. Clin. Oncol."},{"key":"181_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge, M. et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89, 16\u201327 (2012).","journal-title":"Eur J Haematol"},{"key":"181_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos, M. A. et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 98, 784\u2013788 (2013).","journal-title":"Haematologica"},{"key":"181_CR22","doi-asserted-by":"publisher","unstructured":"Stewart, A. K. et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.J. Clin. Oncol. (2016). https:\/\/doi.org\/10.1200\/JCO.2016.66.9648.","DOI":"10.1200\/JCO.2016.66.9648"},{"key":"181_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jclinepi.2005.07.008","volume":"58","author":"KJ Yost","year":"2005","unstructured":"Yost, K. J. et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J. Clin. Epidemiol. 58, 1241\u20131251 (2005).","journal-title":"J. Clin. Epidemiol."},{"key":"181_CR24","unstructured":"Cocks K., Buchanan J. Defining responders on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (30-item core module) (QLQ-C30) subscales. Presented at 22nd Annual Conference for the International Society for Quality of Life Research. (Vancouver, Canada, 2015)."},{"key":"181_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks, K. et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur. J. Cancer 48, 1713\u20131721 (2012).","journal-title":"Eur. J. Cancer"},{"key":"181_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00520-009-0793-1","volume":"19","author":"A Molassiotis","year":"2011","unstructured":"Molassiotis, A., Wilson, B., Blair, S., Howe, T. & Cavet, J. Living with multiple myeloma: experiences of patients and their informal caregivers. Support. Care Cancer 19, 101\u2013111 (2011).","journal-title":"Support. Care Cancer"},{"key":"181_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/pon.1715","volume":"20","author":"B Potrata","year":"2011","unstructured":"Potrata, B. et al. Understanding distress and distressing experiences in patients living with multiple myeloma: an exploratory study. Psychooncology 20, 127\u2013134 (2011).","journal-title":"Psychooncology"},{"key":"181_CR28","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/jan.12430","volume":"70","author":"M Stephens","year":"2014","unstructured":"Stephens, M., McKenzie, H. & Jordens, C. F. The work of living with a rare cancer: multiple myeloma. J. Adv. Nurs. 70, 2800\u20132809 (2014).","journal-title":"J. Adv. Nurs."},{"key":"181_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jval.2012.01.010","volume":"15","author":"C DeMuro","year":"2012","unstructured":"DeMuro, C. et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 15, 443\u2013448 (2012).","journal-title":"Value Health"},{"key":"181_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols, F. et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur. J. Haematol. 89, 311\u2013319 (2012).","journal-title":"Eur. J. Haematol."},{"key":"181_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge, M. et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Hematologica 100, 826\u2013833 (2015).","journal-title":"Hematologica"},{"key":"181_CR32","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen, S. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116, 4745\u20134753 (2010).","journal-title":"Blood"},{"key":"181_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431\u2013440 (2011).","journal-title":"Lancet Oncol."},{"key":"181_CR34","doi-asserted-by":"crossref","unstructured":"Bell, M. L. et al. Differential dropout and bias in randomized controlled trials: when it matters and when it may not. Br. Med. J. 346, e8668 (2013).","DOI":"10.1136\/bmj.e8668"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0181-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:35:29Z","timestamp":1721007329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0181-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0181-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"21 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.L. has received research funding from Amgen and Takeda; received consulting fees from Amgen, Takeda, BMS, Celgene, and Janssen and has served on the speakers\u2019 bureau for Amgen, Takeda, BMS, Celgene, and Janssen. P.M. has received consulting fees from Amgen, Celgene, Takeda, Janssen, BMS, and Novartis. M.A.D. has received consulting fees from Amgen, Celgene, Janssen, Takeda, and Novartis. M.V.M has received consulting fees from Janssen, Celgene, Amgen, Takeda, BMS, and Glicomimetics. M.K. has received consulting fees from Celgene, Takeda, Amgen, BMS, Janssen, and Chugai, and has received research funding from Celgene. R.H. reports research grants from Celgene, Amgen, Novartis, and Takeda; and consulting fees from Janssen, Amgen, and BMS. S.F. and J.B. are employees and equity owners of Amgen. K.C. has received consulting fees from Amgen, Celgene, BMS, and Endomag. K.W. has served on advisory boards for Amgen, Celgene, and Janssen; received consulting fees from BMS, Celgene, Janssen, Novartis, Onyx, and Takeda; and has received research funding from Janssen and Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"23"}}